We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Aligos Therapeutics Inc (ALGS) USD0.0001

Sell:$0.67 Buy:$0.69 Change: $0.0444 (6.93%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.0444 (6.93%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
Change: $0.0444 (6.93%)
Market closed |  Prices as at close on 21 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics to address unmet medical needs in viral infections and liver diseases. It uses its small molecule and oligonucleotide platforms to develop pharmacologically optimized drug candidates for use in combination regimens. Its primary area of focus is on developing functional cure for nonalcoholic steatohepatitis (NASH) and to develop drug candidates with coronavirus activity, as well as seeks to enhance the rate of functional cure for chronic hepatitis B (CHB). It has developed a portfolio of differentiated drug candidates for CHB, including a small molecule capsid assembly modulator (CAM-E) and oligonucleotide small interfering ribonucleic acids (siRNA), each of which is designed against clinically validated targets in the hepatitis B virus (HBV) life cycle. Its pipeline includes ALG-055009 for the treatment of NASH; ALG-000184 and ALG-125755 for CHB, and ALG-097558 for coronavirus.

Contact details

One Corporate Dr., 2nd Floor, 2nd Floor
United States
+1 (302) 6587581

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$48.71 million
Shares in issue:
74.93 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Lawrence Blatt
    Chairman of the Board, Chief Executive Officer
  • Lesley Calhoun
    Chief Financial Officer, Executive Vice President
  • Julian Symons
    Executive Vice President, Chief Scientific Officer
  • Lucinda Quan
    Executive Vice President, Chief Business Officer, General Counsel
  • Matthew Mcclure
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.